CervoMed presents neflamapimod Phase 3 design and MRI data at LBD Annual Meeting

CervoMed Inc.

New MRI analyses from Phase 2b RewinD-LB trial show neflamapimod may reduce basal forebrain atrophy in DLB.
Global regulatory alignment achieved; Phase 3 trial design finalized.
Plasma GFAP biomarker correlates with cognitive decline and is responsive to neflamapimod treatment.
Additional MRI data to be presented at AAN Annual Meeting on April 22, 2026.
No approved treatments for DLB in US or EU; neflamapimod aims to be first.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.